Background/Aims: We performed a prospective non-randomized clinical trial to demonstrate that Interferon (IFN) treatment of individuals with chronic hepatitis C virus (HCV) positive hepatitis (CH-C) and serologic and/or histologic evidence of autoimmune dysregulation is feasible and whether the benefits of successfully treating CH-C are outweighed by the risk of exacerbating Autoimmune Chronic Active Hepatitis (ACAH). Patients and Methods: 23 patients with positive autoimmune dysregulation markers underwent a 6 month course of IFN treatment for chronic HCV hepatitis and were followed for a total of 12 months. Patients were treated with 5 MU of α2b IFN administered subcutaneously 7 days a week for 6 months. Complete blood counts and a panel of liver enzymes were monitored weekly for 4 weeks and then monthly for an additional 11 months (6 months of therapy and 6 months of follow-up). Serum auto-antibodies titers were determined prior to treatment, at the end of the treatment and again after 6 months of follow-up. A liver biopsy was performed prior to, and at the end of treatment and again at 12 months. Results: Using the standard ALT criteria for defining a response to IFN therapy, 14 (61%) patients experienced a full response and 3 (13%) experienced a partial response. Forty-three percent of the full responders and 33% of the partial responders experienced a relapse during the follow-up. The titer of each of the previously positive autoantibodies either remained unchanged or increased by 1 or 2 dilutions. No clinical exacerbations of a co-existent ACAH were observed. Conclusions: Individuals with combined CH-C and one or more markers of autoimmune dysregulation can be treated successfully with IFN. Such treatment does not necessarily increase or exacerbate co-existent ACAH and elevate the serum ALT level. In those who clear HCV-RNA as a result of IFN, the liver histology shifts from one consistant with CH-C to resembling ACAH.

Van Thiel, D., Molloy, P., Friedlander, L., Kania, R., Fagiuoli, S., Caraceni, P., et al. (1995). Iterferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation. HEPATO-GASTROENTEROLOGY, 42(6), 900-906.

Iterferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation.

Fagiuoli, S;
1995

Abstract

Background/Aims: We performed a prospective non-randomized clinical trial to demonstrate that Interferon (IFN) treatment of individuals with chronic hepatitis C virus (HCV) positive hepatitis (CH-C) and serologic and/or histologic evidence of autoimmune dysregulation is feasible and whether the benefits of successfully treating CH-C are outweighed by the risk of exacerbating Autoimmune Chronic Active Hepatitis (ACAH). Patients and Methods: 23 patients with positive autoimmune dysregulation markers underwent a 6 month course of IFN treatment for chronic HCV hepatitis and were followed for a total of 12 months. Patients were treated with 5 MU of α2b IFN administered subcutaneously 7 days a week for 6 months. Complete blood counts and a panel of liver enzymes were monitored weekly for 4 weeks and then monthly for an additional 11 months (6 months of therapy and 6 months of follow-up). Serum auto-antibodies titers were determined prior to treatment, at the end of the treatment and again after 6 months of follow-up. A liver biopsy was performed prior to, and at the end of treatment and again at 12 months. Results: Using the standard ALT criteria for defining a response to IFN therapy, 14 (61%) patients experienced a full response and 3 (13%) experienced a partial response. Forty-three percent of the full responders and 33% of the partial responders experienced a relapse during the follow-up. The titer of each of the previously positive autoantibodies either remained unchanged or increased by 1 or 2 dilutions. No clinical exacerbations of a co-existent ACAH were observed. Conclusions: Individuals with combined CH-C and one or more markers of autoimmune dysregulation can be treated successfully with IFN. Such treatment does not necessarily increase or exacerbate co-existent ACAH and elevate the serum ALT level. In those who clear HCV-RNA as a result of IFN, the liver histology shifts from one consistant with CH-C to resembling ACAH.
Articolo in rivista - Articolo scientifico
Autoimmune dysregulation; Chronic hepatitis C;
English
900
906
7
Van Thiel, D., Molloy, P., Friedlander, L., Kania, R., Fagiuoli, S., Caraceni, P., et al. (1995). Iterferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation. HEPATO-GASTROENTEROLOGY, 42(6), 900-906.
Van Thiel, D; Molloy, P; Friedlander, L; Kania, R; Fagiuoli, S; Caraceni, P; Wright, H; Zuhdi, N
File in questo prodotto:
File Dimensione Formato  
hepato gastro HCV autoimmune 1995.pdf

Solo gestori archivio

Dimensione 3.85 MB
Formato Adobe PDF
3.85 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/354069
Citazioni
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 9
Social impact